Rare and Orphan Diseases - Global Neurology Academy

1-16 of 67

Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
NeuroFrontiers
Recognizing TK2d: Key Clinical Signs and Diagnostic Protocols
Alexandria May, PharmD, BCPS; Kaitlin Batley, MD
- Alexandria May, PharmD, BCPS
- Kaitlin Batley, MD
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
NeuroFrontiers
Identifying the Respiratory Manifestations of TK2d: The Pulmonologist’s Role
Charles Turck, PharmD, BCPS, BCCCP; Bethany Lussier, MD
- Charles Turck, PharmD, BCPS, BCCCP
- Bethany Lussier, MD
Examining the Global Genetic Prevalence of TK2d
Examining the Global Genetic Prevalence of TK2d
NeuroFrontiers
Examining the Global Genetic Prevalence of TK2d
Brian P. McDonough, MD, FAAFP; Austin Larson, MD
- Brian P. McDonough, MD, FAAFP
- Austin Larson, MD
Friedreich’s Ataxia: Impact of Frataxin Loss
Friedreich’s Ataxia: Impact of Frataxin Loss
NeuroFrontiers
Friedreich’s Ataxia: Impact of Frataxin Loss
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Unpacking the Genetics of Friedreich’s Ataxia
Unpacking the Genetics of Friedreich’s Ataxia
NeuroFrontiers
Unpacking the Genetics of Friedreich’s Ataxia
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
Is Friedreich’s Ataxia Developmental or Degenerative?
Is Friedreich’s Ataxia Developmental or Degenerative?
NeuroFrontiers
Is Friedreich’s Ataxia Developmental or Degenerative?
Arnulf Koeppen, MD
- Arnulf Koeppen, MD
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
NeuroFrontiers
SPOTLIGHT Registry Findings on Eculizumab and Ravulizumab in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
NeuroFrontiers
RAISE Subgroup Analysis: Zilucoplan Without Prior Rescue Therapy in gMG
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
NeuroFrontiers
Spinal Muscular Atrophy Reveals Hidden Kidney Impairment Risk
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
NeuroFrontiers
Early ALS Patients Show Slowed Decline with Pridopidine Treatment
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Switching to Risdiplam Maintains Motor Gains in SMA Patients
AudioAbstracts
Switching to Risdiplam Maintains Motor Gains in SMA Patients
Ryan Quigley
- Ryan Quigley
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
NeuroFrontiers
CK1δ Inhibition and Riluzole in ALS: Synergy at Lower Doses
Individualizing gMG Treatment: Defining Success With Each Patient
Individualizing gMG Treatment: Defining Success With Each Patient
NeuroFrontiers
Individualizing gMG Treatment: Defining Success With Each Patient
Omar Sinno, MD
- Omar Sinno, MD
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
NeuroFrontiers
Timing Meningococcal Vaccines in gMG: Challenges and Considerations
Michael Weiss, MD
- Michael Weiss, MD
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
NeuroFrontiers
Optimizing Generalized Myasthenia Gravis Care Through Patient-Centered Choices
Sheetal Shroff, MD
- Sheetal Shroff, MD
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
CME/CE
Optimizing the Role for Corticosteroids Within the Evolving DMD Treatment Landscape
Stephen Chrzanowski, MD, PhD; Aravindhan Veerapandiyan, MD
1.00 credit
- Stephen Chrzanowski, MD, PhD
- Aravindhan Veerapandiyan, MD
1.00 credit

Prev
1
2
3
4
5
Next

1/5